Reply to Ghosh et al1 . Comments on Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder
- PMID: 34773320
- DOI: 10.1111/bdi.13151
Reply to Ghosh et al1 . Comments on Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder
Comment on
-
Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder.Bipolar Disord. 2021 Sep;23(6):595-603. doi: 10.1111/bdi.13041. Epub 2021 Jan 9. Bipolar Disord. 2021. PMID: 33368969 Clinical Trial.
-
Efficacy of endoxifen, a protein kinase C inhibitor for acute and mixed mania: Some concerns worth considering.Bipolar Disord. 2021 Sep;23(6):636. doi: 10.1111/bdi.13109. Epub 2021 Jul 23. Bipolar Disord. 2021. PMID: 34214241 No abstract available.
References
REFERENCES
-
- Ghosh A, Rani S, Grover S. Efficacy of endoxifen, a protein kinase C inhibitor for acute and mixed mania: some concerns worth considering. Bipolar Disord. 2021;6:636.
-
- Ahmad A, Sheikh S, Khan MA, et al. Endoxifen: a new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 2021;6:595-603.
-
- Ahmad A, Sheikh S, Shah T, et al. Endoxifen, a new treatment option for mania: a double-blind, active-controlled trial demonstrates the antimanic efficacy of endoxifen. Clin Transl Sci. 2016;9(5):252-259.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical